Preliminary experience of whole-brain radiation therapy (WBRT) in breast cancer patients with brain metastases previously treated with bevacizumab-based chemotherapy

Journal of Neuro-Oncology

Volumn 105, Issue 2, 2011, Pages 401-408

  Chira, Ciprian ^a   Jacob, Julian ^a   Derhem, Najib ^a   Bollet, Marc A ^a   Campana, François ^a   Marchand, Virginie ^a   Pierga, Jean Yves ^a,b   Fourquet, Alain ^a   Kirova, Youlia M ^a  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Bevacizumab; Metastatic breast cancer; Toxicity; Whole brain radiation therapy

Indexed keywords

BEVACIZUMAB; DOCETAXEL; PACLITAXEL;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BRAIN CANCER; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; NAUSEA; NEUROTOXICITY; RADIATION DOSE; STEREOTAXIC SURGERY; TREATMENT DURATION; VERTIGO; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CHEMORADIOTHERAPY; CRANIAL IRRADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 82955233402     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0607-4     Document Type: Article

References (38)

1. RJ Weil DC Palmieri JL Bronder AM Stark PS Steeg 2005 Breast cancer metastasis to the central nervous system Am J Pathol 167 4 913 920 16192626 10.1016/S0002-9440(10)61180-7 1:CAS:528:DC%2BD2MXhtFKqtLrP (Pubitemid 41416243)
2. Y Tsukada A Fouad JW Pickren WW Lane 1983 Central nervous system metastasis from breast carcinoma. Autopsy study Cancer 52 12 2349 2354 6640506 10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B 1:STN:280:DyaL2c%2FlsV2qtg%3D%3D (Pubitemid 14205961)
3. N Kased DK Binder MW McDermott JL Nakamura K Huang MS Berger WM Wara PK Sneed 2009 Gamma Knife radiosurgery for brain metastases from primary breast cancer Int J Radiat Oncol Biol Phys 75 4 1132 1140 19345514 10.1016/j.ijrobp. 2008.12.031
4. L Gaspar C Scott M Rotman S Asbell T Phillips T Wasserman WG McKenna R Byhardt 1997 Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials Int J Radiat Oncol Biol Phys 37 4 745 751 9128946 10.1016/S0360-3016(96)00619-0 1:STN:280:DyaK2s3nsFSmsA%3D%3D (Pubitemid 27181303)
5. E Weltman JV Salvajoli RA Brandt R de Morais Hanriot FE Prisco JC Cruz SR de Oliveira Borges DB Wajsbrot 2000 Radiosurgery for brain metastases: a score index for predicting prognosis Int J Radiat Oncol Biol Phys 46 5 1155 1161 10725626 10.1016/S0360-3016(99)00549-0 1:STN:280:DC%2BD3c7ptFOlsQ%3D%3D (Pubitemid 30139425)
6. AF Eichler I Kuter P Ryan L Schapira J Younger JW Henson 2008 Survival in patients with brain metastases from breast cancer: the importance of HER-2 status Cancer 112 11 2359 2367 18361426 10.1002/cncr.23468 1:CAS:528: DC%2BD1cXnsFGjtbg%3D
7. SL Hines LA Vallow WW Tan RB McNeil EA Perez A Jain 2008 Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer Ann Oncol 19 9 1561 1565 18534964 10.1093/annonc/mdn283 1:STN:280:DC%2BD1crjtVWnug%3D%3D
8. B Borgelt R Gelber S Kramer LW Brady CH Chang LW Davis CA Perez FR Hendrickson 1980 The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 6 1 1 9 6154024 1:STN:280:DyaL3c7lvFekuw%3D%3D (Pubitemid 10103009)
9. RA Patchell PA Tibbs JW Walsh, et al. 1990 A randomized trial of surgery in the treatment of single metastases to the brain N Engl J Med 322 8 494 500 2405271 10.1056/NEJM199002223220802 1:STN:280:DyaK3c7js1OlsQ%3D%3D (Pubitemid 20067825)
10. RA Patchell PA Tibbs WF Regine, et al. 1998 Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial JAMA 280 17 1485 1489 9809728 10.1001/jama.280.17.1485 1:STN:280:DyaK1M%2FisFKjsg%3D%3D (Pubitemid 28507400)
11. M Kocher R Soffietti U Abacioglu, et al. 2011 Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study J Clin Oncol 29 2 134 141 21041710 10.1200/JCO.2010.30.1655
12. DH Gorski MA Beckett NT Jaskowiak, et al. 1999 Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 14 3374 3378 10416597 1:CAS:528: DyaK1MXks1Oms7s%3D (Pubitemid 29334495)
13. WD Brazelle W Shi DW Siemann 2006 VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy Int J Radiat Oncol Biol Phys 65 3 836 841 16751064 10.1016/j.ijrobp.2006.02.023 1:CAS:528:DC%2BD28XltlGrtbs%3D (Pubitemid 43795843)
14. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NE Davidson 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 26 2666 2676 18160686 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D
15. DW Miles A Chan LY Dirix J Cortés X Pivot P Tomczak T Delozier JH Sohn L Provencher F Puglisi N Harbeck GG Steger A Schneeweiss AM Wardley A Chlistalla G Romieu 2010 Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 20 3239 3247 20498403 10.1200/JCO.2008.21.6457 1:CAS:528:DC%2BC3cXhtVajur3P
16. R Gray S Bhattacharya C Bowden K Miller RL Comis 2009 Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer J Clin Oncol 27 30 4966 4972 19720913 10.1200/JCO.2008.21.6630 1:CAS:528:DC%2BD1MXhsVCrsr%2FJ
17. MM Oken RH Creech DC Tormey J Horton TE Davis ET McFadden PP Carbone 1982 Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 6 649 655 7165009 10.1097/00000421-198212000-00014 1:STN:280:DyaL3s7kvFOgsw%3D%3D (Pubitemid 13149996)
18. Benstette M (2010) European Medicines Agency completes its review of Avastin used in breast cancer treatment. European Medicines Agency web. http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2010/12/ WC500099929.pdf. Accessed 20 Jan 2011
19. Jefferson E (2010) FDA begins process to remove breast cancer indication from Avastin label. Food and Drug Administration web. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm237172.htm. Accessed 20 Jan 2011
20. C Chargari F Campana JY Pierga L Védrine D Ricard S Le Moulec A Fourquet YM Kirova 2010 Whole-brain radiation therapy in breast cancer patients with brain metastases Nat Rev Clin Oncol 7 11 632 640 20625374 10.1038/nrclinonc.2010.119
21. EM Noordijk CJ Vecht H Haaxma-Reiche GW Padberg JH Voormolen FH Hoekstra JT Tans N Lambooij JA Metsaars AR Wattendorff 1994 The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age Int J Radiat Oncol Biol Phys 29 4 711 717 8040016 10.1016/0360-3016(94)90558-4 1:STN:280:DyaK2czhsVGrug%3D%3D (Pubitemid 24241310)
22. Genentech, Inc. (2010) Avastin highlights of prescribing information. Genentech web. http://www.gene.com/gene/products/information/pdf/avastin- prescribing.pdf. Accessed 20 Jan 2011
23. Vidal M (2010) Vidal medical dictionary. OVP Editions Vidal, Paris
24. K Miller M Wang J Gralow, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 18160686 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D
25. Robert NJ, Dieras V et al (2009) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 27:15s (suppl; abstr 1005)
26. O'Shaughnessy J, Miles D et al (2010) A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 28:15s (suppl; abstr 1005)
27. S Goyal MS Rao A Khan L Huzzy C Green BG Haffty 2011 Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab Int J Radiat Oncol Biol Phys 79 2 408 411 20452134 10.1016/j.ijrobp.2009.11.021 1:CAS:528:DC%2BC3MXhtVamsw%3D%3D
28. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2335 2342 15175435 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
29. FF Kabbinavar J Hambleton RD Mass, et al. 2005 Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 3706 3712 15867200 10.1200/JCO.2005.00.232 1:CAS:528:DC%2BD2MXlslWntro%3D
30. Giantonio BJ, Catalano PJ, Meropol NJ et al (2005) High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [Abstract]. J Clin Oncol 23(Suppl.):2
31. MI Koukourakis A Giatromanolaki H Sheldon FM Buffa G Kouklakis I Ragoussis E Sivridis AL Harris 2009 Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab Clin Cancer Res 15 22 7069 7076 19887481 10.1158/1078-0432.CCR-09-0688 1:CAS:528: DC%2BD1MXhtl2ktLfN
32. CG Willett DG Duda E di Tomaso Y Boucher M Ancukiewicz DV Sahani J Lahdenranta DC Chung AJ Fischman GY Lauwers P Shellito BG Czito TZ Wong E Paulson M Poleski Z Vujaskovic R Bentley HX Chen JW Clark RK Jain 2009 Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study J Clin Oncol 27 18 3020 3026 19470921 10.1200/JCO.2008.21.1771 1:CAS:528:DC%2BD1MXoslyisLY%3D
33. F Lordick H Geinitz J Theisen A Sendler M Sarbia 2006 Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases Int J Radiat Oncol Biol Phys 64 5 1295 1298 16503384 10.1016/j.ijrobp.2005.12.004 1:CAS:528:DC%2BD28XjtFWqtr8%3D
34. CH Crane LM Ellis JL Abbruzzese, et al. 2006 Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer J Clin Oncol 24 7 1145 1151 16505434 10.1200/JCO.2005.03.6780 1:CAS:528:DC%2BD28XislGgsbk%3D (Pubitemid 46638812)
35. TY Seiwert DJ Haraf EE Cohen, et al. 2008 Phase I study of bevacizaumab added to fluorouracil- and hydroxyurea-based concomitant chemo radiotherapy, for poor-prognosis head and neck cancer J Clin Oncol 26 1732 1741 18375903 10.1200/JCO.2007.13.1706 1:CAS:528:DC%2BD1cXltlWhs78%3D
36. KC De Braganca YY Jangigian CG Azzoli, et al. 2010 Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer J Neurooncol 100 3 443 447 20440540 10.1007/s11060-010-0200-2
37. MA Socinski CJ Langer JE Huang, et al. 2009 Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases J Clin Oncol 27 31 5255 5261 19738122 10.1200/JCO.2009.22.0616 1:CAS:528:DC%2BD1MXhsFahsLjL
38. Levy C (2010) Tolerance evaluation of bevacizumab and whole brain radiotherapy in the treatment of brain metastases. National Cancer Institute of France web. http://www.e-cancer.fr/recherche/recherche-clinique/registre-des- essais-cliniques